AstraZeneca (AZN) Stock Buyback History
TTM buyback yield 0.16% · Shareholder yield (TTM) 0.16%.
AstraZeneca
AZN
TTM buyback yield
0.16%
Shareholder yield (TTM)
0.16%
5Y share count change
19.0%
TTM buyback spend
$211.58M
SBC coverage (TTM)
N/A
Diluted vs basic shares (annual)
Weighted average shares from the income statement: diluted (EPS denominator and typical buyback-yield basis) compared with basic.
Shares outstanding (annual)
Year-over-year change in diluted weighted average shares (industry-standard for EPS and per-share capital return). Green is fewer shares vs the prior fiscal year; red is growth (dilution). The earliest year shown has no prior year to compare.
Dividend & buyback yield
Buybacks vs stock-based compensation
TTM coverage: N/A (buybacks ÷ SBC). Bars are fiscal-year totals.
Buyback spending history
| Year | Buybacks | SBC | Net | Shares (dil.) | YoY shares | Buyback yield |
|---|---|---|---|---|---|---|
| 2025 | $719.66M | $0.00 | $719.66M | 0.78B | -0.1% | 0.53% |
| 2024 | $0.00 | $0.00 | $0.00 | 0.78B | 0.1% | — |
| 2023 | $0.00 | $579.00M | −$579.00M | 0.78B | 0.1% | — |
| 2022 | $0.00 | $619.00M | −$619.00M | 0.78B | 9.3% | — |
| 2021 | $0.00 | $615.00M | −$615.00M | 0.71B | 8.7% | — |
| 2020 | $0.00 | $277.00M | −$277.00M | 0.66B | 0.9% | — |
| 2019 | $0.00 | $259.00M | −$259.00M | 0.65B | 2.7% | — |
| 2018 | $0.00 | $0.00 | $0.00 | 0.63B | 0.0% | — |
| 2017 | $0.00 | $0.00 | $0.00 | 0.63B | 0.1% | — |
| 2016 | $0.00 | $0.00 | $0.00 | 0.63B | 0.1% | — |
| 2015 | $0.00 | $0.00 | $0.00 | 0.63B | 0.1% | — |
| 2014 | $0.00 | $0.00 | $0.00 | 0.63B | 0.8% | — |
| 2013 | $0.00 | $0.00 | $0.00 | 0.63B | -0.8% | — |
| 2012 | $2.63B | $0.00 | $2.63B | 0.63B | -7.5% | 8.95% |
| 2011 | $6.01B | $0.00 | $6.01B | 0.68B | -5.5% | 19.81% |
| 2010 | $2.60B | $0.00 | $2.60B | 0.72B | -0.3% | 7.96% |
| 2009 | $0.00 | $0.00 | $0.00 | 0.72B | -0.2% | — |
| 2008 | $610.00M | $0.00 | $610.00M | 0.73B | -3.0% | 2.05% |
| 2007 | $4.17B | $0.00 | $4.17B | 0.75B | -4.6% | 13.37% |
| 2006 | $4.15B | $0.00 | $4.15B | 0.79B | -3.0% | 10.20% |
| 2005 | $3.00B | $0.00 | $3.00B | 0.81B | -3.3% | 7.82% |
| 2004 | $2.21B | $0.00 | $2.21B | 0.84B | -2.1% | 7.35% |
| 2003 | $1.11B | $0.00 | $1.11B | 0.85B | -1.5% | 2.76% |
| 2002 | $1.15B | $0.00 | $1.15B | 0.87B | -1.3% | 3.83% |
| 2001 | $1.08B | $0.00 | $1.08B | 0.88B | -0.6% | 2.65% |
| 2000 | $353.98M | $0.00 | $353.98M | 0.88B | -0.5% | — |
| 1999 | $183.00M | $0.00 | $183.00M | 0.89B | 90.2% | — |
| 1998 | $0.00 | $0.00 | $0.00 | 0.47B | -1.8% | — |
| 1997 | $0.00 | $0.00 | $0.00 | 0.48B | 0.4% | — |
| 1996 | $0.00 | $0.00 | $0.00 | 0.47B | — | — |
| 1995 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1994 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1993 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1992 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1991 | $0.00 | $0.00 | $0.00 | — | — | — |
| 1990 | $0.00 | $0.00 | $0.00 | — | — | — |
Buybacks vs dividends (share of cash returned)
Buyback capacity (TTM)
TTM buybacks vs headroom (FCF − dividends, TTM)4% of headroom
Headroom $5.60B (TTM FCF − TTM dividends, clamped at zero).
Frequently asked questions
Does AstraZeneca buy back its own stock?
- Yes, AstraZeneca (AZN) has repurchased shares in recent periods. See the history table and charts on this page for amounts and trends.
How much does AstraZeneca spend on share buybacks?
- Trailing twelve months (TTM) buyback spend is about $211.58M (sum of the last four quarterly cash-flow periods in our data). Figures are illustrative; verify in filings.
What is AstraZeneca's buyback yield?
- TTM buyback yield is about 0.16% (TTM buyback spend divided by market cap at the latest quarter-end in our data).
What is AstraZeneca's shareholder yield?
- Shareholder yield combines dividend yield and buyback yield. For the latest period we show approximately 0.16% combined (TTM-based where available).
Is AstraZeneca diluting shareholders?
- Compare stock-based compensation (SBC) to buybacks in the chart above. Net effect varies by year; see annual buyback vs SBC bars and the history table.
How has AstraZeneca's share count changed?
- Diluted weighted average shares changed by about 19.0% over roughly five fiscal years (annual income statement data).